Journal
COLLOID AND INTERFACE SCIENCE COMMUNICATIONS
Volume 50, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.colcom.2022.100668
Keywords
Vascular calcification; Calciprotein particles; Calcification inhibitor; 2, 3-diphosphoglycerric acid; Myo-inositol hexakisphosphate
Funding
- JSPS KAKENHI [21K09816]
Ask authors/readers for more resources
2,3-Diphospho-D-glyceric acid (2,3-DPG) may act as an endogenous inhibitor, delaying the formation of crystalline calciprotein particles and inhibiting calcification in mouse vascular smooth muscle cells without impacting bone-like nodule formation.
Anionic polyphosphate compounds are well-known to inhibit the formation of hydroxyapatite crystals. Vascular calcification (VC) is associated with an increase in crystalline calciprotein particles (CPPs) in the bloodstream. 2,3-Diphospho-D-glyceric acid (2,3-DPG) is a highly anionic Poly-P compound found in the concave center of erythrocytes where it binds to hemoglobin, thereby reducing oxygen affinity. Since 2.3-DPG exists in plasma, we hypothesized that 2,3-DPG may act as an endogenous inhibitor of VC. In comparison to widely recognized calcification inhibitors such as myo-inositol hexakisphosphate, 2,3-DPG significantly delayed the formation of crystalline CPPs. Additionally, 2,3-DPG inhibited calcification in a mouse vascular smooth muscle cell line (MOVAS) without cytotoxic effects. Taken together with the result that 2,3-DPG did not impact bone-like nodule formation in mouse osteoblast-like MC3T3-E1 cells, these results suggest that 2,3-DPG may inhibit VC selectively.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available